The Use of Placebo-Controlled and Non-inferiority Trials for the Evaluation of New Drugs in the Treatment of Postmenopausal Osteoporosis-Reference-Cited by-同舟云学术

The Use of Placebo-Controlled and Non-inferiority Trials for the Evaluation of New Drugs in the Treatment of Postmenopausal Osteoporosis

Published:2002-01-01 Issue:1 Volume:13 Page:1-5
ISSN:0937-941X
Container-title:Osteoporosis International
language:
Short-container-title:Osteoporosis International

Author:

Delmas P. D.,Calvo G.,Boers M.,Abadie E.,Avouac B.,Kahan A.,Kaufman J. M.,Laslop A.,Lekkerkerker J. F.,Nilsson P.,Van Zwieten-Boot B.,Kreutz G.,Reginster J. Y.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism

Link

http://link.springer.com/content/pdf/10.1007/s198-002-8331-3.pdf

Cited by 29 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ethical challenges raised by osteoporosis-related clinical trials;Journal of Medical Ethics and History of Medicine;2023-12-08

2. Inter- and intraobserver reliabilities and critical analysis of the osteoporotic fracture classification of osteoporotic vertebral body fractures;European Spine Journal;2022-04-05

3. The Use of Intravenous Zoledronate May Reduce Retear Rate after Rotator Cuff Repair in Older Female Patients with Osteoporosis: A First In-Human Prospective Study;Journal of Clinical Medicine;2022-02-05

4. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial;The Lancet;2018-01

5. Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis;Expert Opinion on Pharmacotherapy;2017-11-14